167 related articles for article (PubMed ID: 24464167)
1. Breakthrough cancer pain: the current situation.
Buchanan A; Davies A
Int J Palliat Nurs; 2014 Jan; 20(1):6-8. PubMed ID: 24464167
[TBL] [Abstract][Full Text] [Related]
2. An Observational Research Study to Evaluate the Impact of Breakthrough Cancer Pain on the Daily Lives and Functional Status of Patients.
Twomey F; O'Brien T; O'Reilly M; Bogan C; Fleming J
Ir Med J; 2015 Jun; 108(6):174-6. PubMed ID: 26182800
[TBL] [Abstract][Full Text] [Related]
3. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
Romualdi P; Candeletti S
Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
[TBL] [Abstract][Full Text] [Related]
4. Fentanyl pectin nasal spray for breakthrough cancer pain.
Taylor DR; Gabrail N
Future Oncol; 2012 Feb; 8(2):121-30. PubMed ID: 22335576
[TBL] [Abstract][Full Text] [Related]
5. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
6. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
[TBL] [Abstract][Full Text] [Related]
7. Fentanyl for breakthrough cancer pain: where are we?
Meriggi F; Zaniboni A
Rev Recent Clin Trials; 2013 Mar; 8(1):42-7. PubMed ID: 23259417
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
Zucco F; Bonezzi C; Fornasari D
Adv Ther; 2014 Jul; 31(7):657-82. PubMed ID: 25005168
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough pain in patients with abdominal cancer pain.
Mercadante S; Adile C; Giarratano A; Casuccio A
Clin J Pain; 2014 Jun; 30(6):510-4. PubMed ID: 24281289
[TBL] [Abstract][Full Text] [Related]
10. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
11. How nurses assess breakthrough cancer pain, and the impact of this pain on patients' daily lives--results of a European survey.
Rustøen T; Geerling JI; Pappa T; Rundström C; Weisse I; Williams SC; Zavratnik B; Wengström Y
Eur J Oncol Nurs; 2013 Aug; 17(4):402-7. PubMed ID: 23276599
[TBL] [Abstract][Full Text] [Related]
12. European Oncology Nursing Society breakthrough cancer pain guidelines.
Wengström Y; Geerling J; Rustøen T
Eur J Oncol Nurs; 2014 Apr; 18(2):127-31. PubMed ID: 24369817
[TBL] [Abstract][Full Text] [Related]
13. Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary.
Brogan SE; Winter NB
Pain Med; 2011 Dec; 12(12):1758-68. PubMed ID: 22054042
[TBL] [Abstract][Full Text] [Related]
14. Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies.
Mercadante S; Valle A; Porzio G; Aielli F; Adile C; Ficorella C; Raineri M; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):667-71. PubMed ID: 23551065
[TBL] [Abstract][Full Text] [Related]
15. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
Mercadante S
Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines.
Davies AN; Elsner F; Filbet MJ; Porta-Sales J; Ripamonti C; Santini D; Webber K
BMJ Support Palliat Care; 2018 Sep; 8(3):241-249. PubMed ID: 29875184
[TBL] [Abstract][Full Text] [Related]
17. Reply: A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
Meijler WJ
J Pain Symptom Manage; 2014 Jun; 47(6):e9-10. PubMed ID: 24685722
[No Abstract] [Full Text] [Related]
18. Circadian variation of breakthrough pain in cancer patients.
Saini A; Tucci M; Tampellini M; Maina D; Bouraouia K; Giuliano PL; Termine A; Castellano M; Campagna S; Laciura P; Berruti A
Eur J Pain; 2013 Feb; 17(2):264-70. PubMed ID: 22715071
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain.
Tagami K; Okizaki A; Miura T; Watanabe YS; Matsumoto Y; Morita T; Fujimori M; Kinoshita H
J Palliat Med; 2018 Nov; 21(11):1636-1640. PubMed ID: 29975582
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
